Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 2, 2014, Pages 274-285

  Guo, Baojian ^a   Xu, Daping ^b   Duan, Hongwei ^a   Du, Jing ^a   Zhang, Zaijun ^a   Lee, Simon MingYuen ^b   Wang, Yuqiang ^a  

^a JINAN UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); 6 hydroxydopamine (6 OHDA); Oxidative stress; Parkinson's disease; Tetramethylpyrazine nitrone

Indexed keywords

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; LIGUSTICUM; MALE; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA; ZEBRAFISH;

EID: 84893322835     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00743     Document Type: Article

References (50)

1. Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Novère NL, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov., 5, 845-854 (2006).
2. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol., 8, 1150-1157 (2009).
3. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet, 373, 2055-2066 (2009).
4. Song L, Song W, Schipper HM. Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury. J. Neurosci. Res., 85, 2186-2195 (2007).
5. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S. 6-hydroxydopamine- induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem., 281, 5373-5382 (2005).
6. Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, Silverman RB. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun, 3, 1146 (2012).
7. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov., 3, 205-214 (2004).
8. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord., 11 (Suppl. 1), S9-S15 (2005).
9. Ji Yuan W, Yasuhara T, Shingo T, Muraoka K, Agari T, Kameda M, Uozumi T, Tajiri N, Morimoto T, Jing M, Baba T, Wang F, Leung H, Matsui T, Miyoshi Y, Date I. Neuroprotective effects of edar-avone- administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci., 9, 75 (2008).
10. Zhang ZJ, Cheang LC, Wang MW, Lee SM. Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. Int. J. Mol. Med., 27, 195-203 (2011).
11. Youdim MB, Geldenhuys WJ, Van der Schyf CJ. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat. Disord., 13 (Suppl. 3), S281-S291 (2007).
12. Tan Z. Neural protection by naturopathic compounds-an example of tetramethylpyrazine from retina to brain. J. Ocul. Biol. Dis. Infor., 2, 57-64 (2009).
13. Hu JZ, Huang JH, Xiao ZM, Li JH, Li XM, Lu HB. Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation. J. Neurol. Sci., 324, 94-99 (2013).
14. Kao TK, Chang CY, Ou YC, Chen WY, Kuan YH, Pan HC, Liao SL, Li GZ, Chen CJ. Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp. Neurol., 247, 188-201 (2013).
15. Ren Z, Ma J, Zhang P, Luo A, Zhang S, Kong L, Qian C. The effect of ligustrazine on L-type calcium current, calcium transient and contractility in rabbit ventricular myocytes. J. Ethnopharmacol., 144, 555-561 (2012).
16. Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci., 72, 2465-2472 (2003).
17. Shih YH, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS. Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. Neuroreport, 13, 515-519 (2002).
18. Chang Y, Hsiao G, Chen SH, Chen YC, Lin JH, Lin KH, Chou DS, Sheu JR. Tetramethylpyrazine suppresses HIF-1α, TNF-α, and activated caspase-3 expression in middle cerebral artery occlusioninduced brain ischemia in rats. Acta Pharmacol. Sin., 28, 327-333 (2007).
19. Liao SL, Kao TK, Chen WY, Lin YS, Chen SY, Raung SL, Wu CW, Lu HC, Chen CJ. Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci. Lett., 372, 40-45 (2004).
20. Zhang C, Wang SZ, Zuo PP, Cui X, Cai J. Protective effect of tetramethylpyrazine on learning and memory function in D-galactoselesioned mice. Chin. Med. Sci. J., 19, 180-184 (2004).
21. Wang DQ, Wang W, Jing FC. Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of LDOPA in rats with Parkinson's disease. Zhongguo Zhong Xi Yi Jie He Za Zhi, 27, 629-632 (2007).
22. Floyd RA, Castro Faria Neto HC, Zimmerman GA, Hensley K, Towner RA. Nitrone-based therapeutics for neurodegenerative diseases: Their use alone or in combination with lanthionines. Free Radic. Biol. Med., 62, 145-156 (2013).
23. Saito K, Kobayashi C, Ikeda M. Effect of radical scavenger N-tertbutyl-alpha-phenylnitrone on stroke in a rat model using a telemetric system. J. Pharm. Pharm. Sci., 11, 25-31 (2008).
24. Yang J, Ahn HN, Chang M, Narasimhan P, Chan PH, Song YS. Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J. Neurochem., 124, 523-535 (2013).
25. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med., 357, 562-571 (2007).
26. Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, Liu W, Wang Y. Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg. Med. Chem., 16, 8868-8874 (2008).
27. Sun Y, Yu P, Zhang G, Wang L, Zhong H, Zhai Z, Wang Y, Wang Y. Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models. J. Neurosci. Res., 90, 1662-1669 (2012).
28. Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, Tian Z, Wright SC, Larrick JW, Wang Y. Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur. J. Med. Chem., 44, 2936-2943 (2009).
29. Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J., 22, 2488-2497 (2008).
30. Hung MW, Zhang ZJ, Li S, Lei B, Yuan S, Cui GZ, Man Hoi P, Chan K, Lee SM. From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound. Evid. Based Complement. Alternat. Med., 2012, 605303 (2012).
31. Cui W, Zhang Z, Li W, Hu S, Mak S, Zhang H, Han R, Yuan S, Li S, Sa F, Xu D, Lin Z, Zuo Z, Rong J, Ma ED, Choi TC, Lee SM, Han Y. The anti-cancer agent SU4312 unexpectedly protects against MPP(+)-induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br. J. Pharmacol., 168, 1201-1214 (2013).
32. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N -methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem., 78, 1073-1082 (2001).
33. Zhao Q, Gao J, Li W, Cai D. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease. Brain Res., 1346, 224-236 (2010).
34. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc., 2, 141-151 (2007).
35. Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci., 24, 2045-2053 (2004).
36. He XJ, Yamauchi H, Uetsuka K, Nakayama H. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease. Neurotoxicology, 29, 413-420 (2008).
37. Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J. Neural Transm., 115, 831-842 (2008).
38. Zhang Z, Cui W, Li G, Yuan S, Xu D, Hoi MP, Lin Z, Dou J, Han Y, Lee SM. Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCalpha and PI3K/AKT signaling pathways. J. Agric. Food Chem., 60, 8171-8182 (2012).
39. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 447, 1081-1086 (2007).
40. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res., 162, 1-10 (2005).
41. Endoh H, Kato N, Fujii S, Suzuki Y, Sato S, Kayama T, Kotake Y, Yoshimura T. Spin trapping agent, phenyl N-tert-butylnitrone, reduces nitric oxide production in the rat brain during experimental meningitis. Free Radic. Res., 35, 583-591 (2001).
42. Durand G, Choteau F, Pucci B, Villamena FA. Reactivity of superoxide radical anion and hydroperoxyl radical with alpha-phenyl-N-tert-butylnitrone (PBN) derivatives. J. Phys. Chem. A, 112, 12498-12509 (2008).
43. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitritemediated reperfusion injury. J. Biol. Chem., 271, 29223-29230 (1996).
44. Trachootham D, Lu W, Ogasawara MA, Valle NR-D, Huang P. Redox regulation of cell survival. Antioxid. Redox Signal., 10, 1343-1374 (2008).
45. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol., 48, 1-19 (1996).
46. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann. Neurol., 44 (Suppl. 1), S72-S84 (1998).
47. George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, Finkelstein DI. Targeting the progression of Parkinson's disease. Curr. Neuropharmacol., 7, 9-36 (2009).
48. Ganapathy PS, White RE, Ha Y, Bozard BR, McNeil PL, Caldwell RW, Kumar S, Black SM, Smith SB. The role of N-methyl-D-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci., 52, 5515-5524 (2011).
49. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. Ltype calcium channel blockers and Parkinson's disease in Denmark. Ann. Neurol., 67, 600-606 (2010).
50. Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, Videnovic A, Weaver FM, Williams K, Surmeier DJ. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord., 25, 2863-2866 (2010).